FDA Proposes Withdrawing FloLipid Cholesterol Drug Approval

The agency cites Salerno Pharmaceuticals' repeated failure to file required annual reports for the liquid cholesterol medication.

Updated on Nov. 17, 2026 in Heart Disease

Bold flat-color vector editorial illustration of an amber dropper bottle beside a stack of manila folders on a cream field, suggesting a regulatory filing matter.
The FDA proposed withdrawing approval of Salerno Pharmaceuticals' liquid cholesterol drug FloLipid after the company repeatedly failed to file required annual reports. AI Illustration. Upload story photo >

The U.S. Food and Drug Administration has proposed withdrawing approval for Salerno Pharmaceuticals' liquid cholesterol medication FloLipid. The proposal, published in a Federal Register notice on Tuesday, follows the company's repeated failure to file required annual reports and its lack of response to the agency's request.

Why it matters

FloLipid is formulated as a liquid alternative for people who have difficulty swallowing pills, so a withdrawal would affect patients who rely on that form of a blood cholesterol lowering medication. The action also underscores that drug manufacturers with approved products must keep their required FDA reporting current.

The action is documented in a Federal Register notice published Tuesday, November 17, 2026, which formally begins the proposed withdrawal process. The source does not state how many patients use FloLipid or whether Salerno has responded to the proposal, leaving the medication's future availability unresolved.

The players

U.S. Food and Drug Administration

The federal agency responsible for regulating drugs, medical devices and food in the United States, including reviewing and approving new drug applications and monitoring approved products.

Salerno Pharmaceuticals

The drugmaker that manufactures FloLipid, a blood cholesterol lowering medication sold in liquid form.

The details

The FDA's drug evaluation department proposed withdrawal of approval through a Federal Register notice, basing the proposal on Salerno's repeated failure to file required annual reports for FloLipid. Companies with an approved drug for human use must submit these annual reports concerning their approved new drug application, and Salerno has not responded to the agency's request for the reports. Salerno will be given an opportunity for a hearing to show why approval should not be withdrawn.

Timeline

  1. Tuesday, November 17, 2026: FDA's proposal to withdraw approval for FloLipid was published in a Federal Register notice.

Heart Disease Landscape

The proposal enforces the FDA's requirement that companies with approved new drug applications submit annual reports, and it places a blood cholesterol medication, a treatment class used to reduce heart disease risk, under that oversight. Withdrawal would remove one option for lowering cholesterol from the market while the hearing process runs.

Patients who take FloLipid, or who have difficulty swallowing pills and rely on its liquid form, may need to discuss alternative cholesterol-lowering options with their doctors if the approval is withdrawn. The outcome of the hearing process will determine whether the medication remains available.

The takeaway

Patients on any prescription medication should keep their clinicians informed about changes to their treatment and watch for official notices about approval status. Manufacturer reporting obligations are part of keeping approved drugs on the market.

What happens next

Salerno Pharmaceuticals will be given an opportunity for a hearing to show why approval should not be withdrawn; no hearing date has been set in the source.

Further reading

Explore more on Heart Disease coverage from across the United States.